Prof. Dr. Beat Thürlimann
Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann B, Bernhard J, Hsu Schmitz S, Schmid H. Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study. European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32.
01.08.2002Vinorelbine in androgen-independent metastatic prostatic carcinoma--a phase II study
01.08.2002European journal of cancer (Oxford, England : 1990) 2002; 38:1626-32
Morant R, Hering F, Bauer J, Hanselmann S, Jacky E, Streit A, Forrer P, Egli F, Wernli M, Borner M, Thürlimann Beat, Bernhard J, Hsu Schmitz S-F, Schmid H-P
Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
Colleoni M, Collins J, Thürlimann B, Holmberg S, Crivellari D, Beyerle C, Neumann R, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C, Litman H, Castiglione-Gertsch M, Sauerbrei W, Gelber R, Bonetti M, Coates A, Schumacher M, Bastert G, German Breast Cancer Study Group. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. British journal of cancer 2002; 86:1705-14.
05.06.2002Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
05.06.2002British journal of cancer 2002; 86:1705-14
Colleoni M, Collins J, Thürlimann Beat, Holmberg S B, Crivellari D, Beyerle C, Neumann R L A, Goldhirsch A, International Breast Cancer Study Group, Lindtner J, Schmoor C, Rudenstam C-M, Litman H J, Castiglione-Gertsch M, Sauerbrei W, Gelber R D, Bonetti M, Coates A S, Schumacher M, Bastert G, German Breast Cancer Study Group
Patients' estimation of overall treatment burden: why not ask the obvious?
Bernhard J, Maibach R, Thürlimann B, Sessa C, Aapro M, Swiss Group for Clinical Cancer Research. Patients' estimation of overall treatment burden: why not ask the obvious?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72.
01.01.2002Patients' estimation of overall treatment burden: why not ask the obvious?
01.01.2002Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002; 20:65-72
Bernhard J, Maibach R, Thürlimann Beat, Sessa C, Aapro M S, Swiss Group for Clinical Cancer Research
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann B, Robertson J, Nabholtz J, Buzdar A, Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92:2247-58.
01.11.2001Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
01.11.2001Cancer 2001; 92:2247-58
Bonneterre J, Arimidex Writing Committee, Steinberg M, Webster A, Sahmoud T, von Euler M, Thürlimann Beat, Robertson J F, Nabholtz J M, Buzdar A, Investigators Committee Members
Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Gelber S, International Breast Cancer Study Group. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9.
01.11.2001Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
01.11.2001Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001; 19:4141-9
Colleoni M, Goldhirsch A, Fey M, Murray E, Simoncini E, Cortes-Funes H, Holmberg S B, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Gelber S, International Breast Cancer Study Group
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
Köberle D, Thürlimann B. Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer. Expert review of anticancer therapy 2001; 1:169-76.
01.08.2001Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer
01.08.2001Expert review of anticancer therapy 2001; 1:169-76
Köberle Dieter, Thürlimann Beat
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group. High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6.
01.03.2001High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
01.03.2001Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001; 12:353-6
Crivellari D, Goldhirsch A, Sessa C, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Nolé F, Lombardi D, Veronesi A, Pagani O, International Breast Cancer Study Group
International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
Thürlimann B. International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland. Breast cancer (Tokyo, Japan) 2001; 8:294-7.
01.01.2001International consensus meeting on the treatment of primary breast cancer 2001, St. Gallen, Switzerland
01.01.2001Breast cancer (Tokyo, Japan) 2001; 8:294-7
Thürlimann Beat
Identifying breast cancer patients at high risk for bone metastases
Colleoni M, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R, Bonetti M, Thürlimann B, Price K, Castiglione-Gertsch M, Coates A, Rudenstam C. Identifying breast cancer patients at high risk for bone metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35.
01.12.2000Identifying breast cancer patients at high risk for bone metastases
01.12.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3925-35
Colleoni M, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, O'Neill A, Goldhirsch A, Gelber R D, Bonetti M, Thürlimann Beat, Price K N, Castiglione-Gertsch M, Coates A S, Rudenstam C M
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57.
15.11.2000Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
15.11.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:3748-57
Bonneterre J, Steinberg M, Webster A, Vergote I, Koralewski P, Mauriac L, Krzakowski M, Robertson J F, Thürlimann Beat, von Euler M
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann B, Bonneterre J, von Euler M. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5.
01.09.2000Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
01.09.2000European journal of cancer (Oxford, England : 1990) 2000; 36 Suppl 4:S84-5
Vergote I, Steinberg M, Webster A, Koralewski L, Mauriac L, Krzakowski M, Robertson J, Thürlimann Beat, Bonneterre J, von Euler M
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess D, Thürlimann B, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91.
01.08.2000Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
01.08.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:985-91
Pagani O, D'Incalci M, Zucchetti M, Graffeo R, Martinelli G, Bauer J, Borner M, Hess Dagmar, Thürlimann Beat, Lombardi D, Crivellari D, Nolé F, Sessa C, Goldhirsch A
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 2000; 355:1869-74.
27.05.2000Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
27.05.2000Lancet 2000; 355:1869-74
Aebi S, Coates A S, Werner I D, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C M, Thürlimann Beat, Collins J, Gelber R D, Castiglione-Gertsch M, Gelber S, Goldhirsch A
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
Crivellari D, Senn H, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R, Rudenstam C, Thürlimann B, Price K, Coates A, Hürny C, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22.
01.04.2000Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII
01.04.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:1412-22
Crivellari D, Senn H J, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Collins J, Lindtner J, Bernhard J, Bonetti M, Castiglione-Gertsch M, Gelber R D, Rudenstam C M, Thürlimann Beat, Price K N, Coates A S, Hürny C, Goldhirsch A
Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
Gessner U, Köberle D, Thürlimann B, Bacchus L, Horisberger B. Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22.
01.03.2000Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate
01.03.2000Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000; 8:115-22
Gessner U, Köberle Dieter, Thürlimann Beat, Bacchus L, Horisberger B
Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
Sabbioni M, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Castiglione M, Bernhard J, Bacchi M, Siegrist H, Hürny C. Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment. Breast cancer research and treatment 2000; 59:279-87.
01.02.2000Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment
01.02.2000Breast cancer research and treatment 2000; 59:279-87
Sabbioni M E, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann Beat, Castiglione M, Bernhard J, Bacchi M, Siegrist H P, Hürny C
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann B, Fey M, Borner M, Maibach R, Bernhard J, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8.
01.02.2000Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
01.02.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann Beat, Fey M F, Borner M, Maibach R, Bernhard J, Hering F
Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann B, Collins J, Lindtner J, Rudenstam C, Price K, Gelber R, Castiglione-Gertsch M, Coates A, Bonetti M, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:584-90.
01.02.2000Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
01.02.2000Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000; 18:584-90
Colleoni M, Marini G, Veronesi A, Holmberg S, Thürlimann Beat, Collins J, Lindtner J, Rudenstam C M, Price K, Gelber R D, Castiglione-Gertsch M, Coates A S, Bonetti M, Goldhirsch A
Small-cell lung cancer with brain metastases and survival for more than 15 years despite incomplete therapy
Ruhstaller T, Thürlimann B. Small-cell lung cancer with brain metastases and survival for more than 15 years despite incomplete therapy. Onkologie 2000; 23:64-66.
01.02.2000Small-cell lung cancer with brain metastases and survival for more than 15 years despite incomplete therapy
01.02.2000Onkologie 2000; 23:64-66
Ruhstaller Thomas, Thürlimann Beat
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy
Rizzoli R, Eghbali H, Clemens M, Thürlimann B, Degardin M, Steinhauer E, Tubiana-Hulin M, Manegold C, Rückert F, Huss H, Herrmann Z, Pecherstorfer M, Bundred N, Thiébaud D, Body J. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. The Journal of clinical endocrinology and metabolism 1999; 84:3545-50.
01.10.1999Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy
01.10.1999The Journal of clinical endocrinology and metabolism 1999; 84:3545-50
Rizzoli R, Eghbali H, Clemens M R, Thürlimann Beat, Degardin M, Steinhauer E U, Tubiana-Hulin M, Manegold C, Rückert F, Huss H J, Herrmann Z, Pecherstorfer M, Bundred N, Thiébaud D, Body J J